Latest News - Valeant

Tuesday, January 02, 2018

Pershing Square, Valeant to Pay $290 Million to End Lawsuit

Activist investor Bill Ackman’s Pershing Square Holdings Ltd. and Valeant Pharmaceuticals International Inc. agreed to pay $290 million to settle investor claims that they engaged in insider tra…

Read the full story

Monday, December 18, 2017

Bausch + Lomb Begins Distribution Of Vyzulta To US Wholesalers

Bausch + Lomb announced that it has begun distributing Vyzulta (latanoprostene bunod ophthalmic solution) .024% to US wholesale pharmaceutical distributors. Vyzulta will be available to patients acros…

Read the full story

Wednesday, November 08, 2017

Valeant Profit Beats on Bausch & Lomb Strength

Valeant Pharmaceuticals reported a better-than-expected quarterly profit on strength in its Bausch and Lomb eye-care business, and the Canadian drugmaker maintained its full-year adjusted earnings for…

Read the full story

Thursday, November 02, 2017

Bausch + Lomb And Nicox Announce FDA Approval of Glaucoma Treatment Vyzulta

Bausch + Lomb and Nicox announced that the FDA has approved Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), indicated for the reduction of IOP in patients with open-angle glaucoma or o…

Read the full story

Wednesday, August 16, 2017

FDA: Inspection Issues at Bausch + Lomb Manufacturing Plant in Tampa Facility are Being Resolved

Valeant announced that the FDA confirmed it intends to issue a Voluntary Action Indicated (VAI) inspection classification for its Bausch + Lomb manufacturing facility in Tampa. With this confirmation,…

Read the full story

Tuesday, August 08, 2017

FDA Rejects Valeant's Marketing Application for IOP Eye Drop Latanoprostene Bunod

In a complete response letter (CRL) to Valeant, the FDA did not approve the new drug application (NDA) for latanoprostene bunod ophthalmic solution, 0.024%, citing Current Good Manufacturing Prac…

Read the full story

Tuesday, June 20, 2017

Valeant Investor John Paulson Appointed to Board

Valeant Pharmaceuticals announced Monday that John Paulson has been elected to serve as a director, bringing the total number of independent members on the company's board to 10. Mr. Paulson is pr…

Read the full story

Tuesday, June 06, 2017

Report: Valeant in Talks to Sell Bausch + Lomb's Surgical Business to Carl Zeiss

Valeant is in in talks to sell its Bausch & Lomb unit’s surgical products business to Carl Zeiss Meditec, according to a Bloomberg report, which cited people familiar with the matter. Valean…

Read the full story

Tuesday, May 09, 2017

Bausch + Lomb Announces PDUFA Date For Luminesse

Bausch + Lomb announced that the FDA accepted the new drug application (NDA) for brimonidine tartrate ophthalmic solution, 0.025% (Luminesse), and set a PDUFA action date of December 27, 2017. Lumines…

Read the full story

Thursday, March 30, 2017

Bausch + Lomb Announces US Management Team Leadership

Bausch + Lomb announced several changes to its management team designed to improve operational efficiencies. Joseph “Joe” Gordon, senior vice president and general manager, US Consumer …

Read the full story

Thursday, March 30, 2017

Ackman: Investment in Valeant a 'Huge Mistake'

In his annual letter to investors of his hedge fund, Bill Ackman “deeply and profoundly” apologized for his investment in Valeant, a move that ultimately cost Pershing Square Capital Manag…

Read the full story

Tuesday, March 28, 2017

Former Valeant CEO Michael Pearson Sues Company Over Unpaid Share Award

Former Valeant Pharmaceuticals CEO Michael Pearson filed a lawsuit in the US claiming that the company failed to deliver 3 million shares promised to him as part of an exit package. According to the c…

Read the full story

Tuesday, March 14, 2017

Ackman Unloads Entire Stake in Valeant

After a long relationship that has seen the rapid rise and massive fall of Valeant’s stock price, Pershing Square Capital Management CEO Bill Ackman stated that his hedge fund has sold all its s…

Read the full story

Tuesday, February 21, 2017

Valeant and Eyegate Enter into Licensing Agreement for EyeGate II Delivery System and EGP-437 Combination Product

Valeant Pharmaceuticals International and EyeGate Pharmaceuticals announced that they have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Va…

Read the full story

Thursday, December 01, 2016

Valeant Drops After Report Salix Sale Discussions Broke Down

Valeant Pharmaceuticals International Inc. dropped after a report that discussions to sell its gastrointestinal drugs unit to Japan’s Takeda Pharmaceutical Co. for about $10 billion have fallen …

Read the full story
Load More